These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 17335685)
1. Role of bone marrow transplantation in the disease pathway of myeloma. Harousseau JL; Moreau P J Natl Compr Canc Netw; 2007 Feb; 5(2):163-9. PubMed ID: 17335685 [TBL] [Abstract][Full Text] [Related]
3. High complete remission rate and durable remissions achieved with rational use of autologous stem-cell transplantation, thalidomide maintenance, and non-myeloablative allogeneic transplantation in patients with multiple myeloma. Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E Clin Transplant; 2009; 23(6):839-47. PubMed ID: 20447186 [TBL] [Abstract][Full Text] [Related]
4. Evolving role of stem cell transplantation in multiple myeloma. Harousseau JL; Moreau P Clin Lymphoma Myeloma; 2005 Sep; 6(2):89-95. PubMed ID: 16231846 [TBL] [Abstract][Full Text] [Related]
5. First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studies. Naumann-Winter F; Greb A; Borchmann P; Bohlius J; Engert A; Schnell R Cochrane Database Syst Rev; 2012 Oct; 10(10):CD004626. PubMed ID: 23076906 [TBL] [Abstract][Full Text] [Related]
6. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Kim HJ; Yoon SS; Lee DS; Sohn SK; Eom HS; Lee JL; Chung JS; Kim K; Suh C; Won JH; Kim JS; Park JS; Kang HJ; Seong CM; Kim CS; Lee SJ; Lee JH Ann Hematol; 2012 Feb; 91(2):249-56. PubMed ID: 21789621 [TBL] [Abstract][Full Text] [Related]
7. Autologous stem cell transplantation in first remission is associated with better progression-free survival in multiple myeloma. Aggarwal M; Agrawal N; Yadav N; Verma P; Ahmed R; Mehta P; Kapoor J; Bhurani D Ann Hematol; 2018 Oct; 97(10):1869-1877. PubMed ID: 29781040 [TBL] [Abstract][Full Text] [Related]
8. [Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma]. Huang B; Li J; Liu J; Gu J; Zheng D; Xu D; Zou W; Wang H Zhonghua Nei Ke Za Zhi; 2014 Nov; 53(11):865-72. PubMed ID: 25586356 [TBL] [Abstract][Full Text] [Related]
11. The role of tandem stem cell transplantation for multiple myeloma patients. Martino M; Recchia AG; Fedele R; Neri S; Vincelli ID; Moscato T; Gentile M; Morabito F Expert Opin Biol Ther; 2016; 16(4):515-34. PubMed ID: 26698133 [TBL] [Abstract][Full Text] [Related]
12. Role of autologous stem cell transplantation in multiple myeloma. Kumar S Curr Hematol Malig Rep; 2007 May; 2(2):121-7. PubMed ID: 20425360 [TBL] [Abstract][Full Text] [Related]
13. Bortezomib-based strategy with autologous stem cell transplantation for newly diagnosed multiple myeloma: a phase II study by the Japan Study Group for Cell Therapy and Transplantation (JSCT-MM12). Sunami K; Matsumoto M; Fuchida SI; Omoto E; Takamatsu H; Adachi Y; Choi I; Fujishima N; Kiguchi T; Miyamoto T; Maeda A; Suzumiya J; Yamamura R; Nagafuji K; Nakazato T; Kuroda Y; Yujiri T; Takamatsu Y; Harada M; Akashi K Int J Clin Oncol; 2019 Aug; 24(8):966-975. PubMed ID: 30937622 [TBL] [Abstract][Full Text] [Related]
14. Multiple myeloma: chemotherapy or transplantation in the era of new drugs. Palumbo A; Rajkumar SV Eur J Haematol; 2010 May; 84(5):379-90. PubMed ID: 20345446 [TBL] [Abstract][Full Text] [Related]
16. [First-line treatment of multiple myeloma]. Breitkreutz I; Raab M; Goldschmidt H Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458 [TBL] [Abstract][Full Text] [Related]
17. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation. Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH; Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634 [TBL] [Abstract][Full Text] [Related]
18. Comparable outcome of stem cell transplant versus bortezomib-based consolidation in myeloma patients after major response to induction. Gao W; Geng C; Zhang L; Li Y; Chen W; Wang C Hematology; 2013 Nov; 18(6):341-7. PubMed ID: 23510553 [TBL] [Abstract][Full Text] [Related]
19. Integrating novel therapies in the transplant paradigm. Harousseau JL Cancer J; 2009; 15(6):479-84. PubMed ID: 20010167 [TBL] [Abstract][Full Text] [Related]
20. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Sahebi F; Frankel PH; Farol L; Krishnan AY; Cai JL; Somlo G; Thomas SH; Reburiano E; Popplewell LL; Parker PM; Spielberger RT; Kogut NM; Karanes C; Htut M; Ruel C; Duarte L; Murata-Collins JL; Forman SJ Biol Blood Marrow Transplant; 2012 Mar; 18(3):486-92. PubMed ID: 22198542 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]